The company
Alumis Inc.
ALMS · Nasdaq
ALMS stood above a rising 150-day average in 36 of the last 52 weekly readings, and has been out of that trend for the last 9 weeks. It is 69.5% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 9
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $103.4M
- Insider sales, 12 months
- $3.1M
- Officials’ trades on record
- 0
- Institutions holding
- 191 (+4)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 36 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Srinivas AkkarajuDirector | sold | 48,066at $10.55 | 8 Sep 2026filed 9 Sep 2026 |
| Srinivas AkkarajuDirector | sold | 48,065at $10.55 | 8 Sep 2026filed 9 Sep 2026 |
| Srinivas AkkarajuDirector | bought | 273,291at $10.63 | 8 Sep 2026filed 9 Sep 2026 |
| Srinivas AkkarajuDirector | bought | 273,290at $10.63 | 8 Sep 2026filed 9 Sep 2026 |
| Srinivas AkkarajuDirector | bought | 220,070at $11.17 | 4 Sep 2026filed 9 Sep 2026 |
| Srinivas AkkarajuDirector | bought | 220,070at $11.17 | 4 Sep 2026filed 9 Sep 2026 |
| Roy C. HardimanChief Business & Strategy Ofcr | sold | 2,692at $26.37 | 3 Aug 2026filed 5 Aug 2026 |
| John R. SchroerChief Financial Officer | sold | 3,282at $26.37 | 3 Aug 2026filed 5 Aug 2026 |
| David M. GoldsteinChief Scientific Officer | sold | 2,596at $26.37 | 3 Aug 2026filed 5 Aug 2026 |
| Jorn DrappaChief Medical Officer | sold | 2,447at $26.37 | 3 Aug 2026filed 5 Aug 2026 |
| Mark Christopher BradleyChief Development Officer | sold | 2,572at $26.37 | 3 Aug 2026filed 5 Aug 2026 |
| Sanam PangaliChief Legal Officer | sold | 1,364at $26.37 | 3 Aug 2026filed 5 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| AyurMaya Capital Management Company, LPunchanged · filed 13 Aug 2026 | 15,139,707$426.0M | 00.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 8,218,151$231.3M | +1,047,283+14.6% |
| FMR LLCadded · filed 13 Aug 2026 | 6,769,170$190.5M | +5,795,388+595.1% |
| Deep Track Capital, LPreduced · filed 14 Aug 2026 | 6,348,558$178.6M | -424,037−6.3% |
| SAMSARA BIOCAPITAL, LLCunchanged · filed 14 Aug 2026 | 6,345,219$178.6M | 00.0% |
| Foresite Capital Management V, LLCunchanged · filed 14 Aug 2026 | 5,896,995$165.9M | 00.0% |
| venBio Partners LLCunchanged · filed 14 Aug 2026 | 4,528,408$127.4M | 00.0% |
| Foresite Capital Management VI LLCunchanged · filed 14 Aug 2026 | 4,247,670$119.5M | 00.0% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 4,215,703$118.6M | +183,437+4.5% |
| Nextech Invest Ltd.unchanged · filed 14 Aug 2026 | 3,540,998$99.6M | 00.0% |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.